NFE2L2 and acute lymphoblastic leukemia: In acute lymphoblastic leukemia, only very recently, a study published by Wang and colleagues observed that NRF2 overexpression in B-ALL patients could decrease therapeutic response to vincristine, one of the chemotherapeutic agents commonly used in B-ALL treatment.